DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Appeal No. 7108 of 2026 filed by Meera Devi

SEBI 1 hr ago·13 Oct 2026, 12:31 pm

Company SEBI

A legal appeal has been filed by an individual named Meera Devi, raising concerns that could impact a specific company. The case, Appeal No. 7108 of 2026, is currently being reviewed by the relevant authorities. The nature of the appeal and the exact legal issues involved are not yet fully detailed in the public domain.

This development is significant for investors as it introduces a layer of uncertainty regarding the company's future. Any adverse legal ruling could potentially affect the company's operations, reputation, and financial performance. Investors should monitor the progress of this case to understand its implications for the stock.

Moving forward, the focus should be on official updates from the court and the company. Investors are advised to wait for more concrete information before making any investment decisions. Keeping a close watch on regulatory announcements will be crucial during this period.